...
首页> 外文期刊>BMC Cancer >Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy
【24h】

Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy

机译:糖尿病和癌症发病风险:意大利北部基于人群的队列研究结果

获取原文

摘要

Aim of this study was to compare cancer incidence in populations with and without diabetes by cancer site. Furthermore, we aimed at comparing excess risk of cancer according to diabetes type, diabetes duration and treatment, the latter as regards Type 2 diabetes. By use of the Reggio Emilia diabetes registry we classified the resident population aged 20–84 at December 31st 2009 into two groups: with and without diabetes. By linking with the cancer registry we calculated the 2010–2013 cancer incidence in both groups. The incidence rate ratios (IRR) by cancer site, type of diabetes, diabetes duration, and as concerns Type 2 diabetes, by treatment regimen were computed using Poisson regression model and non-diabetic group as reference. The cohort included 383,799 subjects without diabetes and 23,358 with diabetes. During follow-up, we identified 1464 cancer cases in subjects with diabetes and 9858 in the remaining population. Overall cancer incidence was higher in subjects with diabetes than in those without diabetes (IRR?=?1.22, 95%CI 1.15–1.29), with similar results focusing on subjects with at least 2-year diabetes duration. Cancer sites driving overall increased risk were liver, pancreas, Colon rectum, and bladder in both sexes, corpus uteri for females. There was also suggestion of an increased risk for kidney cancer in females and a decreased risk for prostate cancer. Excess risk was found in patients with Type 2 diabetes, more marked among insulin users, especially with combined therapy. We observed an increasing risk for diabetes duration up to 10?years from diagnosis (IRR?=?1.44, 95%CI 1.29–1.61) and a subsequent decrease to moderate-higher risk (IRR?=?1.15, 95%CI 1.04–1.30). Our study indicates that the strength of association depends on specific cancer site. Insulin, monotherapy or combined therapy, per se or as an indication of poor blood glucose control, in addition to diabetes duration, may play a role in the association of diabetes and cancer.
机译:本研究的目的是通过癌症部位比较有无糖尿病人群的癌症发生率。此外,我们的目的是根据糖尿病类型,糖尿病持续时间和治疗方法比较癌症的额外风险,后者与2型糖尿病有关。通过使用Reggio Emilia糖尿病注册中心,我们将2009年12月31日年龄在20-84岁的常住人口分为两组:有和没有糖尿病。通过与癌症登记处的链接,我们计算了两组的2010-2013年癌症发病率。使用泊松回归模型和非糖尿病组作为参考,通过癌症治疗方案,癌症部位,糖尿病类型,糖尿病持续时间以及有关2型糖尿病的发生率比率(IRR)进行计算。该队列包括383799名无糖尿病患者和23358名糖尿病患者。在随访过程中,我们确定了1464例糖尿病患者的癌症病例和9858例其余人群的癌症病例。糖尿病患者的总体癌症发病率高于非糖尿病患者(IRR?=?1.22,95%CI 1.15–1.29),相似的结果集中于糖尿病持续时间至少为两年的患者。导致总体风险增加的癌症部位是男女的肝,胰腺,结肠直肠和膀胱,女性为子宫体。也有人建议女性患肾癌的风险增加,而前列腺癌的风险降低。在2型糖尿病患者中发现了较高的风险,在胰岛素使用者中尤为明显,尤其是联合治疗。我们发现,从诊断到长达10年的糖尿病持续时间的风险增加(IRR?=?1.44,95%CI 1.29–1.61),随后降低到中度较高的风险(IRR?=?1.15,95%CI 1.04– 1.30)。我们的研究表明,关联的强度取决于特定的癌症部位。除糖尿病持续时间外,胰岛素本身,单一疗法或联合疗法本身或作为血糖控制不良的指标可能在糖尿病和癌症的关联中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号